补肾活血化痰法对冠心病患者颈动脉斑块的影响研究
|
摘要
冠心病(冠状动脉粥样硬化性心脏病)多发生于中老年人,随着人民生活条件改善与膳食习惯的改变,冠心病的发病率已趋向年轻化。目前,它与脑卒中同为我国致残和死亡率最高的疾病,严重地威胁人们生命和健康。大量研究证实,颈动脉粥样硬化与冠状动脉粥样硬化有着相同的病理基础,两者关系密切,颈动脉粥样硬化性病变是全身动脉粥样硬化性疾病的窗口,因为颈动脉粥样硬化的发生要较冠状动脉粥样硬化为早。早期的冠心病,可以没有任何症状,临床上诊断非常困难,因而患者常常得不到适当和及时治疗。随着近年超声检查仪器和方法的完善,利用无创的颈动脉超声检查预测冠心病,达到早期有效地发现和治疗动脉粥样硬化的目的,对防治冠心病与一系列心脑血管疾病非常重要。中医药治疗冠心病与颈动脉粥样硬化有一定的特色和优势,而补肾活血化痰法更已广泛应用在冠心病心绞痛的治疗和预防之中。本研究拟探讨以“补肾活血化痰汤”治疗冠心病心绞痛患者的同时,观察研究补肾活血化痰法对患者颈动脉粥样硬化斑块的影响,以及其它相关心脑血管病症(如头痛、眩晕、视力下降、记忆力衰退等等)的治疗效果。“补肾活血化痰汤”是我校附属深圳市中医院心血管内科疾病专家、广东省名中医,导师罗陆一教授集四十多年临床经验,既充份考虑到动脉粥样硬化的病理特性,又顾虑其危险因素,并结合中老年人体质多虚的特点,以肾虚为本,瘀血、痰阻为标的机理立论,经多年验证创制而成的纯中药汤剂。是方由熟地黄、补骨脂、制首乌、怀牛膝、制半夏、制南星、石菖蒲、川芎、三七等中药组成。
目的：
研究中药汤剂“补肾活血化痰汤”对冠心病心绞痛的疗效及对患者颈动脉粥样硬化斑块的影响,从而进一步证实“补肾活血化痰汤”的临床疗效,为中医治疗冠心病心绞痛及颈动脉硬化斑块患者提供有疗效的新方法、新制剂。方法：
选取冠心病心绞痛患者共192例,并且符合诊断、纳入标准的患者(颈动脉内中膜厚度IMT≧1mm或是颈动脉粥样硬化斑块患者),采用随机数字表法,按住院号顺序随机分为中药“补肾活血化痰汤”治疗组T、“阿托伐他汀钙”西药对照组A、和基础治疗基础组B。三组均给予基础治疗用药：口服“阿司匹林”每日1片(每片100mg),晚上服用。治疗组T采用补肾活血化痰汤治疗,每日1剂,分早晚两次温服。对照组A给予口服“阿托伐他汀钙”每日1片(每片lOmg),晚上服用。基础组B只给予基础治疗用药。各组均以90天为1个疗程。连续观察2个疗程。比较各组治疗前后颈动脉粥样硬化斑块数量、类型、内中膜厚度IMT、斑块面积、斑块Crouse积分,观察各组治疗前后临床症状、心绞痛症状、心电图、肝肾功能、电解质、血、尿和大便等三大常规指标,血脂总胆固醇TC、甘油三脂TG、高密度脂蛋白胆固醇HDL-C、低密度脂蛋白胆固醇LDL-C、C反应蛋白CRP、与血流变的指标。再作统计学分析,得出结果,完成临床研究。
结果：
治疗组T补肾活血化痰汤治疗后,在颈动脉粥样硬化疗效上,显效率46.03%,总有效率为83.87%,与对照组A比较则无显著性差异(P>0.05),而与基础组B比较,则有非常显著差异(P<0.01)；各类型斑块数目均明显下降,斑块总数由128个降到89个,有非常显著差异(P<0.01),与对照组A比较则无显著性差异(P>0.05),而与基础组B比较,则有非常显著差异(P<0.01)；治疗组T治疗后内中膜厚度(IMT)、斑块面积、Crouse积分均明显下降,有非常显著差异(P<0.01),但与对照组A、基础组B比较(除基础组B, Crouse积分外)则无显著性差异(P>0.05),治疗组T在Crouse积分比较基础组B,则有非常显著差异(P<0.01)；在心绞痛疗效上,治疗组T痊愈率42.86%,显效率50.79%,总有效率为87.30%；心电图改善显效率52.38%,总有效率为87.30%。心绞痛程度改善、心绞痛临床症状积分改善、心电图疗效、及心绞痛总体疗效均明显优于阿托伐他汀钙对照组A及基础治疗基础组B,有非常显著差异(均P<0.01)；在中医临床症状总体疗效上,治疗组T显效率47.62%,总有效率为85.71%。治疗组T治疗后,各项中医临床症状除记忆力衰退一项外,P=0.000<0.01,有非常显著性差异。中医临床症状总体积分改善、个别症状积分改善(除记忆力衰退、视力下降外)、及中医临床症状总体疗效均明显优于对照组A及基础组B,有非常显著差异(P<0.01)或显著差异(P<0.05)；在调控血脂方面,治疗组T患者治疗后甘油三脂TG、总胆固醇TC、低密度脂蛋白胆固醇LDL-C均得到明显降低,高密度脂蛋白胆固醇HDL-C明显升高,有非常显著差异(均P<0.01),但与对照组A比较则无显著性差异(均P>0.05),而与基础组B比较TG、HDL-C有非常显著差异(均P<0.01),TC、LDL-C则无显著差异(均P>0.05)；在降低炎症因子C反应蛋白值上,治疗组T患者治疗后,CRP值明显下降,有非常显著差异(P<0.01),与对照组A比较则无显著性差异(P>0.05),而与基础组B比较,则有非常显著差异(P<0.01)；在血液流变学指标改善上,治疗组T治疗后,全血粘度(高切)、全血粘度(低切)、红细胞压积、血浆比粘度均明显下降,有非常显著差异(P<0.01),与对照组A、基础组B比较(除血浆比粘度外)则无显著性差异(P>0.05),但血浆比粘度比较则有非常显著性差异(P<0.01)。最后,经直线相关分析,结果显示心绞痛症状积分值和相应的颈动脉内中膜厚度IMT的相关系数为0.819,P=0.000,有统计学意义。可以认为心绞痛症状积分值与颈动脉内中膜厚度呈正相关性。
结论：
补肾活血化痰汤治疗冠心病心绞痛疗效显著,未发现毒性副作用,安全可靠。除治疗心绞痛外,患者颈动脉粥样硬化症状亦显著得到改善。补肾活血化痰汤且具有调脂、降低炎症因子,改善血液流变学指标作用,能减少或抑制颈动脉粥样硬化斑块的形成,并可改善心脑血管疾病的整体临床症状,从而达到抑制颈动脉、以致整体动脉粥样硬化,顾护心脑血管,防范治疗心肌缺血,脑缺血,预防心脑血管事故的发生。最后,本研究显示心绞痛症状积分值和相应的颈动脉内中膜厚度呈正相关性,可以认为心绞痛与颈动脉粥样硬化关系密切。
Coronary Atherosclerotic Heart Disease CAD is mostly happen to middle-aged or older people, with improvement in people's living condition and c hange of their diet habit, there is a trend of increasingly younger peopl e having CAD. Today CAD and Stroke are two main diseases that lead to hig hest rate of disability and death in China, and continue be a major threa t to peoples'health and lives. A large number of research have concluded that Carotid Arterioles Atherosclerosis CAS and CAD have same dangerous f actors and common mechanism, there are close relationships between the tw o. CAS happens earlier than other Arthroscleroses AS, and thus can be use d as a window to detect CAD. Early stages CAD are normally with no sympto m and very difficult to detect, therefore most patient missed proper and timely treatment. Nowadays with the advancement in ultrasonic technology and method, the ultrasonic scanning of CAS become an effective method of detecting CAD in its early stage, and this is very important to prevent a nd decrease incidences of CAD and most Cardiovascular and Cerebrovascular Diseases CCVD. Traditional Chinese Medicine has its superiority and dist inction in treatment of CAD and CAS diseases, and Bushenhuoxuehuatan meth od has already been widely used in treatment of Angina Pectoris. This res earch is an innovative study; the value is to study the curative effects on Atherosclerotic plaque in Carotid artery when treating patients of Ang ina Pectoris of CAD by Bushenhuoxuehuatan Decoction, and at the same tim e investigate the curative effect on other CCVD symptoms as well. Bushenh uoxuehuatan Decoction is invented by my tutor, Guangdong famous TCM prac titioner, Specialist of Internal medicine Shenzhen Hospital of TCM, Profe ssor LUO Luyi, the decoction is a pure Chinese medicine composition and h as been tested and refined for over forty years of clinical practices tre ating AS diseases. Based on the concept that root cause of AS is kidney i nsufficiency, and the incidental factors are blood stasis, and phlegm-hu mor stagnation, Professor LUO tailored the decoction which mainly compose d of Rehmannia glutinosa, Psoralea corylifolia, Polygonum multiflorum, Ac hyranthes bidentata Blume, Pinellia ternate, Arisaema consanguineum Schot t., Acorus gramineus Soland and Ligusticum chuanxiong Hort.
Purpose:
Observing the curative effects on Atherosclerotic plaque in Carotid artery when treating Angina Pectoris patients with Bushenhuoxuehuatan Decoction, thus to provide additional research justification for the effectiveness and refinement of the decoction.
Methods:
192 valid patients were divided into treatment group T, control group A and foundation group B by the simple randomization. All cases for all thr ee groups were given the same foundation treatment:Apsin (one 100mg tabl et at night per day).The treatment group T was treated with Bushenhuoxueh uatan Decoction (one dose per day separately half portion warmly taken mo rning and at night), while control group A was treated by the Atorvastati n calcium (one 10mg tablet at night per day) and foundation group B was t reated only by foundation treatment.90 days would be a course of treatme nt for all three groups, and two courses of treatment were observed. The type and quantities of CAS plaques, intima-media thickness (IMT), plaques area and Crouse scores were detected by Ultrasonic scanning. The patient s'symptoms, Angina Pectoris symptoms, electrocardiogram, hepatic functio n, renal function, electrolytes examination and the three main routine ex aminations before and after the treatment of the three groups were detect ed. And as well as hemo-axungia examination, C-reactive protein measureme nt and hemorheology examination were detected as well. Then, the data woul d be analyzed by statistical analysis to get the results and conclusion.
Result:
The curative effect of the Bushenhuoxuehuatan Decoction is described as follow:For CAS curative effect, predominant effect rate 46.03%, total effect rate 83.87%, there are no significant difference with Atorvastatin calcium control group A(P>0.05), but there are very significant difference with foundation treatment foundation group B(P<0.01). Treatment group T has significantly reduced the quantities of plaques for all types of CAS plaques, total quantity reduced from 128 to 89, there are very significant difference before and after treatment(P<0.01), and there are no significant difference with control group A(P>0.05), but there are very significant difference with foundation group B(P<0.01). Treatment group T has very significantly reduced the intima-media thickness (IMT), very significantly reduced plaques area and very significantly reduced Crouse scores, there are very significant difference (P<0.01). However there are no significant difference between treatment group T and control group A & foundation group B (P>0.05), except on Crouse scores that Treatment group T and foundation group B has very significant difference(P<0.01); Angina Pectoris cure rate 42.86%, predominant effect rate 50.79%, total effect rate 87.3%. Electrocardiogram predominant effect rate 52.38%, total effect rate 87.3%. For curative effect on the extend of Angina Pectoris attacks, Angina Pectoris symptoms, Electrocardiogram cure rate, and the total Angina Pectoris cure rate, Bushenhuoxuehuatan Decoction treatment group is more effective than Atorvastatin calcium control group A and foundation treatment foundation group B, there is very significant difference between treatment group T and the two other groups (P<0.01); Total TCM Symptom Integral predominant effect rate 47.62%, total effect rate 85.71%. All individual TCM Symptom are improved after treatment except memory improvement, (P<0.01), there is very significant difference. Treatment group is more effective than two other groups except memory and eyesight improvements, there are very significant and significant difference between the groups (P<0.01 or P<0.05); In hemo-axungia examination, treatment group T has significant curative effect in lowering TG, TC, LDL-C, while rising HDL-C values, there are very significant difference (P<0.01) after treatment. However there are no significant difference with control group A (P>0.05), and no significant difference with foundation group B (P>0.05)on TC, LDL-C, but has very significant difference with foundation group B (P<0.01) on TG, HDL-C; After treatment, treatment group T has significant reduced C-reactive protein (CRP) value, there are very significant difference (P<0.01). Compared to control groups, there are no significant difference with control group A (P>0.05), but has very significant difference with foundation group B (P<0.01); In hemorheology examination, treatment group has significantly reduced blood viscosity (high and low cut), plasma viscosity, and hematocrit, there are very significant difference (P<0.01). However there are no significant difference between treatment and two other groups (P>0.05) except for plasma viscosity there are very significant difference between treatment and control groups (P<0.01). Finally after straight line correlation analysis, Angina Pectoris symptom scores and IMT has shown direct positive relationship, correlation factor 0.819, P=0.000<0.01, has very significant statistical meaning.
Conclusions:
The Bushenhuoxuehuatan Decoction has outstanding curative effect on Angina Pectoris of Coronary Heart Disease, and at the same time all CAS symptoms of the patient were significantly improved, in the entire course of treatment no adverse drug reaction was observed. Bushenhuoxuehuatan Decoction, with its functions of adjusting the hemo-axungia, reduce C-reactive protein and improving hemorheology, could hinder and defer CAS plaque development, improve symptoms of CCVD, protect and cure CAS and AS diseases, and ultimately prevent and decrease incidences of CAD and most CCVD Diseases
目的：
研究中药汤剂“补肾活血化痰汤”对冠心病心绞痛的疗效及对患者颈动脉粥样硬化斑块的影响,从而进一步证实“补肾活血化痰汤”的临床疗效,为中医治疗冠心病心绞痛及颈动脉硬化斑块患者提供有疗效的新方法、新制剂。方法：
选取冠心病心绞痛患者共192例,并且符合诊断、纳入标准的患者(颈动脉内中膜厚度IMT≧1mm或是颈动脉粥样硬化斑块患者),采用随机数字表法,按住院号顺序随机分为中药“补肾活血化痰汤”治疗组T、“阿托伐他汀钙”西药对照组A、和基础治疗基础组B。三组均给予基础治疗用药：口服“阿司匹林”每日1片(每片100mg),晚上服用。治疗组T采用补肾活血化痰汤治疗,每日1剂,分早晚两次温服。对照组A给予口服“阿托伐他汀钙”每日1片(每片lOmg),晚上服用。基础组B只给予基础治疗用药。各组均以90天为1个疗程。连续观察2个疗程。比较各组治疗前后颈动脉粥样硬化斑块数量、类型、内中膜厚度IMT、斑块面积、斑块Crouse积分,观察各组治疗前后临床症状、心绞痛症状、心电图、肝肾功能、电解质、血、尿和大便等三大常规指标,血脂总胆固醇TC、甘油三脂TG、高密度脂蛋白胆固醇HDL-C、低密度脂蛋白胆固醇LDL-C、C反应蛋白CRP、与血流变的指标。再作统计学分析,得出结果,完成临床研究。
结果：
治疗组T补肾活血化痰汤治疗后,在颈动脉粥样硬化疗效上,显效率46.03%,总有效率为83.87%,与对照组A比较则无显著性差异(P>0.05),而与基础组B比较,则有非常显著差异(P<0.01)；各类型斑块数目均明显下降,斑块总数由128个降到89个,有非常显著差异(P<0.01),与对照组A比较则无显著性差异(P>0.05),而与基础组B比较,则有非常显著差异(P<0.01)；治疗组T治疗后内中膜厚度(IMT)、斑块面积、Crouse积分均明显下降,有非常显著差异(P<0.01),但与对照组A、基础组B比较(除基础组B, Crouse积分外)则无显著性差异(P>0.05),治疗组T在Crouse积分比较基础组B,则有非常显著差异(P<0.01)；在心绞痛疗效上,治疗组T痊愈率42.86%,显效率50.79%,总有效率为87.30%；心电图改善显效率52.38%,总有效率为87.30%。心绞痛程度改善、心绞痛临床症状积分改善、心电图疗效、及心绞痛总体疗效均明显优于阿托伐他汀钙对照组A及基础治疗基础组B,有非常显著差异(均P<0.01)；在中医临床症状总体疗效上,治疗组T显效率47.62%,总有效率为85.71%。治疗组T治疗后,各项中医临床症状除记忆力衰退一项外,P=0.000<0.01,有非常显著性差异。中医临床症状总体积分改善、个别症状积分改善(除记忆力衰退、视力下降外)、及中医临床症状总体疗效均明显优于对照组A及基础组B,有非常显著差异(P<0.01)或显著差异(P<0.05)；在调控血脂方面,治疗组T患者治疗后甘油三脂TG、总胆固醇TC、低密度脂蛋白胆固醇LDL-C均得到明显降低,高密度脂蛋白胆固醇HDL-C明显升高,有非常显著差异(均P<0.01),但与对照组A比较则无显著性差异(均P>0.05),而与基础组B比较TG、HDL-C有非常显著差异(均P<0.01),TC、LDL-C则无显著差异(均P>0.05)；在降低炎症因子C反应蛋白值上,治疗组T患者治疗后,CRP值明显下降,有非常显著差异(P<0.01),与对照组A比较则无显著性差异(P>0.05),而与基础组B比较,则有非常显著差异(P<0.01)；在血液流变学指标改善上,治疗组T治疗后,全血粘度(高切)、全血粘度(低切)、红细胞压积、血浆比粘度均明显下降,有非常显著差异(P<0.01),与对照组A、基础组B比较(除血浆比粘度外)则无显著性差异(P>0.05),但血浆比粘度比较则有非常显著性差异(P<0.01)。最后,经直线相关分析,结果显示心绞痛症状积分值和相应的颈动脉内中膜厚度IMT的相关系数为0.819,P=0.000,有统计学意义。可以认为心绞痛症状积分值与颈动脉内中膜厚度呈正相关性。
结论：
补肾活血化痰汤治疗冠心病心绞痛疗效显著,未发现毒性副作用,安全可靠。除治疗心绞痛外,患者颈动脉粥样硬化症状亦显著得到改善。补肾活血化痰汤且具有调脂、降低炎症因子,改善血液流变学指标作用,能减少或抑制颈动脉粥样硬化斑块的形成,并可改善心脑血管疾病的整体临床症状,从而达到抑制颈动脉、以致整体动脉粥样硬化,顾护心脑血管,防范治疗心肌缺血,脑缺血,预防心脑血管事故的发生。最后,本研究显示心绞痛症状积分值和相应的颈动脉内中膜厚度呈正相关性,可以认为心绞痛与颈动脉粥样硬化关系密切。
Coronary Atherosclerotic Heart Disease CAD is mostly happen to middle-aged or older people, with improvement in people's living condition and c hange of their diet habit, there is a trend of increasingly younger peopl e having CAD. Today CAD and Stroke are two main diseases that lead to hig hest rate of disability and death in China, and continue be a major threa t to peoples'health and lives. A large number of research have concluded that Carotid Arterioles Atherosclerosis CAS and CAD have same dangerous f actors and common mechanism, there are close relationships between the tw o. CAS happens earlier than other Arthroscleroses AS, and thus can be use d as a window to detect CAD. Early stages CAD are normally with no sympto m and very difficult to detect, therefore most patient missed proper and timely treatment. Nowadays with the advancement in ultrasonic technology and method, the ultrasonic scanning of CAS become an effective method of detecting CAD in its early stage, and this is very important to prevent a nd decrease incidences of CAD and most Cardiovascular and Cerebrovascular Diseases CCVD. Traditional Chinese Medicine has its superiority and dist inction in treatment of CAD and CAS diseases, and Bushenhuoxuehuatan meth od has already been widely used in treatment of Angina Pectoris. This res earch is an innovative study; the value is to study the curative effects on Atherosclerotic plaque in Carotid artery when treating patients of Ang ina Pectoris of CAD by Bushenhuoxuehuatan Decoction, and at the same tim e investigate the curative effect on other CCVD symptoms as well. Bushenh uoxuehuatan Decoction is invented by my tutor, Guangdong famous TCM prac titioner, Specialist of Internal medicine Shenzhen Hospital of TCM, Profe ssor LUO Luyi, the decoction is a pure Chinese medicine composition and h as been tested and refined for over forty years of clinical practices tre ating AS diseases. Based on the concept that root cause of AS is kidney i nsufficiency, and the incidental factors are blood stasis, and phlegm-hu mor stagnation, Professor LUO tailored the decoction which mainly compose d of Rehmannia glutinosa, Psoralea corylifolia, Polygonum multiflorum, Ac hyranthes bidentata Blume, Pinellia ternate, Arisaema consanguineum Schot t., Acorus gramineus Soland and Ligusticum chuanxiong Hort.
Purpose:
Observing the curative effects on Atherosclerotic plaque in Carotid artery when treating Angina Pectoris patients with Bushenhuoxuehuatan Decoction, thus to provide additional research justification for the effectiveness and refinement of the decoction.
Methods:
192 valid patients were divided into treatment group T, control group A and foundation group B by the simple randomization. All cases for all thr ee groups were given the same foundation treatment:Apsin (one 100mg tabl et at night per day).The treatment group T was treated with Bushenhuoxueh uatan Decoction (one dose per day separately half portion warmly taken mo rning and at night), while control group A was treated by the Atorvastati n calcium (one 10mg tablet at night per day) and foundation group B was t reated only by foundation treatment.90 days would be a course of treatme nt for all three groups, and two courses of treatment were observed. The type and quantities of CAS plaques, intima-media thickness (IMT), plaques area and Crouse scores were detected by Ultrasonic scanning. The patient s'symptoms, Angina Pectoris symptoms, electrocardiogram, hepatic functio n, renal function, electrolytes examination and the three main routine ex aminations before and after the treatment of the three groups were detect ed. And as well as hemo-axungia examination, C-reactive protein measureme nt and hemorheology examination were detected as well. Then, the data woul d be analyzed by statistical analysis to get the results and conclusion.
Result:
The curative effect of the Bushenhuoxuehuatan Decoction is described as follow:For CAS curative effect, predominant effect rate 46.03%, total effect rate 83.87%, there are no significant difference with Atorvastatin calcium control group A(P>0.05), but there are very significant difference with foundation treatment foundation group B(P<0.01). Treatment group T has significantly reduced the quantities of plaques for all types of CAS plaques, total quantity reduced from 128 to 89, there are very significant difference before and after treatment(P<0.01), and there are no significant difference with control group A(P>0.05), but there are very significant difference with foundation group B(P<0.01). Treatment group T has very significantly reduced the intima-media thickness (IMT), very significantly reduced plaques area and very significantly reduced Crouse scores, there are very significant difference (P<0.01). However there are no significant difference between treatment group T and control group A & foundation group B (P>0.05), except on Crouse scores that Treatment group T and foundation group B has very significant difference(P<0.01); Angina Pectoris cure rate 42.86%, predominant effect rate 50.79%, total effect rate 87.3%. Electrocardiogram predominant effect rate 52.38%, total effect rate 87.3%. For curative effect on the extend of Angina Pectoris attacks, Angina Pectoris symptoms, Electrocardiogram cure rate, and the total Angina Pectoris cure rate, Bushenhuoxuehuatan Decoction treatment group is more effective than Atorvastatin calcium control group A and foundation treatment foundation group B, there is very significant difference between treatment group T and the two other groups (P<0.01); Total TCM Symptom Integral predominant effect rate 47.62%, total effect rate 85.71%. All individual TCM Symptom are improved after treatment except memory improvement, (P<0.01), there is very significant difference. Treatment group is more effective than two other groups except memory and eyesight improvements, there are very significant and significant difference between the groups (P<0.01 or P<0.05); In hemo-axungia examination, treatment group T has significant curative effect in lowering TG, TC, LDL-C, while rising HDL-C values, there are very significant difference (P<0.01) after treatment. However there are no significant difference with control group A (P>0.05), and no significant difference with foundation group B (P>0.05)on TC, LDL-C, but has very significant difference with foundation group B (P<0.01) on TG, HDL-C; After treatment, treatment group T has significant reduced C-reactive protein (CRP) value, there are very significant difference (P<0.01). Compared to control groups, there are no significant difference with control group A (P>0.05), but has very significant difference with foundation group B (P<0.01); In hemorheology examination, treatment group has significantly reduced blood viscosity (high and low cut), plasma viscosity, and hematocrit, there are very significant difference (P<0.01). However there are no significant difference between treatment and two other groups (P>0.05) except for plasma viscosity there are very significant difference between treatment and control groups (P<0.01). Finally after straight line correlation analysis, Angina Pectoris symptom scores and IMT has shown direct positive relationship, correlation factor 0.819, P=0.000<0.01, has very significant statistical meaning.
Conclusions:
The Bushenhuoxuehuatan Decoction has outstanding curative effect on Angina Pectoris of Coronary Heart Disease, and at the same time all CAS symptoms of the patient were significantly improved, in the entire course of treatment no adverse drug reaction was observed. Bushenhuoxuehuatan Decoction, with its functions of adjusting the hemo-axungia, reduce C-reactive protein and improving hemorheology, could hinder and defer CAS plaque development, improve symptoms of CCVD, protect and cure CAS and AS diseases, and ultimately prevent and decrease incidences of CAD and most CCVD Diseases
引文
[1]孟景春,王新华.黄帝内经灵枢译释.上海：上海科学技术出版社,2006.355.
[2]黄志杰,姚昌绶,俞小平.黄帝内经神农本草经中藏经脉经难经.北京：科学技术文献出版社,1999.108.
[3]葛洪.肘后备急方.北京：人民卫生出版社,1983.112.
[4]高文铸.医经病源诊法名着集成.北京：华夏出版社,1994.386.
[5]周一谋,萧佐桃.马王堆医书考注.天津：天津科学技术出版社,1988.10,16.
[6]牛兵占,肖正权.黄帝内经素问译注.北京：中医古籍出版社,2003.464.
[7]张登本,孙理军等.全注全译黄帝内经(下册)灵枢经.北京：新世界出版社,2008.138.
[8]孟景春,王新华.黄帝内经灵枢译释.上海：上海科学技术出版社,2006.119.
[9]黄志杰,姚昌绶,俞小平.黄帝内经神农本草经中藏经脉经难经.北京：科学技术文献出版社,1999.316.
[10]高文铸.医经病源诊法名着集成.北京：华夏出版社,1994.318.
[11]黄志杰,姚昌绶,俞小平.黄帝内经神农本草经中藏经脉经难经.北京：科学技术文献出版社,1999.831.
[12]赵佶.圣济总录(上册).北京：人民卫生出版社,1982.1020,1022.
[13]张家礼.金匮要略.北京：中国中医药出版社,2004.167.
[14]喻昌.医门法律.北京：人民卫生出版社,2006.98.
[15]牛兵占,肖正权.黄帝内经素问译注.北京：中医古籍出版社,2003.441.
[16]印会河,张伯讷.中医基础理论.台北：知音出版社,1981.203.
[17]张登本,孙理军等.全注全译黄帝内经(上册)素问.北京：新世界出版社，2008.535-536.
[18]黄志杰,姚昌绶,俞小平.黄帝内经神农本草经中藏经脉经难经.北京：科学技术文献出版社,1999.8.
[19]牛兵占,肖正权.黄帝内经素问译注.北京：中医古籍出版社,2003.43.
[20]孙思邈.备急千金要方.山西：山西科学技术出版社.2010
[21]牛兵占,肖正权.黄帝内经素问译注.北京：中医古籍出版社,2003.192.
[22]张登本,孙理军等.全注全译黄帝内经(上册)素问.北京：新世界出版社,2008.31.
[23]孟景春,王新华.黄帝内经灵枢译释.上海：上海科学技术出版社,2006.91.
[24]张登本,孙理军等.全注全译黄帝内经(下册)灵枢经.北京：新世界出版社,2008.176.
[25]沈金鳌.杂病源流犀烛.北京：中国中医药出版社,1994.78.
[26]王怀隐.太平圣惠方.北京：人民卫生出版社,1982.
[27]秦景明.症因脉治.北京：人民卫生出版社,2006.71
[28]黄志杰,姚昌绶,俞小平.黄帝内经神农本草经中藏经脉经难经.北京：科学技术文献出版社,1999.99.
[29]李洪涛,等.《杂病广要·胸痹心痛》.北京：中医古籍出版社,2002.1082
[30]张家礼.金匮要略.北京：中国中医药出版社,2004.168.
[31]喻昌.医门法律.北京：人民卫生出版社,2006.99.
[32]叶天士.临证指南医案.上海：上海科学技术出版社,1959.298.
[33]林佩琴.《类证治裁·胸痹》.北京：人民卫生出版社,2005.364.
[34]张家礼.金匮要略.北京：中国中医药出版社,2004.170.
[35]朱震亨.《丹溪心法·痰饮》.北京：人民卫生出版社,2005.71.
[36]张家礼.金匮要略.北京：中国中医药出版社,2004.349.
[37]王清任.医林改错.北京：人民卫生出版社,2005.40
[38]张登本,孙理军等.全注全译黄帝内经(上册)素问.北京：新世界出版社,2008.93.
[39]孟景春,王新华.黄帝内经灵枢译释.上海：上海科学技术出版社,2006.412-413.
[40]张家礼.金匮要略.北京：中国中医药出版社,2004.168-177.
[41]孙思邈.备急千金要方.北京：人民卫生出版社,1982.239-244.
[42]危亦林.世医得效方.北京：人民卫生出版社,2006.124.
[43]王肯堂.证治准绳.北京：人民卫生出版社,1991.142.
[44]林佩琴.类证治裁.北京：人民卫生出版社,2005.367.
[45]王清任.医林改错.北京：人民卫生出版社,2005.23-24.
[46]程国彭.医学心悟.北京：人民卫生出版社,2006.155.
[47]罗陆一.从肾论治冠心病机理例析.中医药学刊,2005；23(4)：588—589.
[48]罗陆一.冠心病从肾论治.中国社区医师，2003；19(22)：33.
[49]张京春.陈可冀院士治疗冠心病心绞痛学术思想与经验.中西医结合心脑血管病杂志,2005：3(7)：634—636.
[50]张京春.陈可冀院士治疗冠心病心绞痛学术思想与经验(续完).中西医结合心脑血管病杂志,2005；3(8)：712—713.
[51]吴岳.董克礼教授诊治中老年冠心病经验.湖南中医杂志,2006；22(1)：20.
[52]吴焕林.心脾相关论与心血管疾病.北京：人民卫生出版社,2004.3-120.
[53]林晓忠,等.邓铁涛教授论治冠心病规律探要.中医药学刊,2001：19(5)：412.
[54]韩学杰.沈绍功教授从痰论治冠心病经验.中国中医急症,2004；13(1)：31.
[55]刘红旭,等.名老中医心血管疾病治疗经验集.北京：军事医学科学出版社,2009.1-15.
[56]魏铁力.颜德馨教授辨治冠心病的独特经验.实用中医内科杂 志,1996：10(1)：1-3.
[57]颜干麟.颜德馨中医心脑病诊治精粹.北京：人民卫生出版社,2009.20-23.
[58]刘红旭,等.名老中医心血管疾病治疗经验集.北京：军事医学科学出版社,2009.163-170.
[59]龙云,等.程丑夫教授治疗冠心病经验.中国中医急症,2004；13(7)：450.
[60]严季澜.孔光一教授治疗冠心病的经验.贵阳中医学院学报,2006；28(6)：17.
[61]张晓军.周宜轩教授治疗冠心病经验.安徽中医学院学报,2004；23(1)：24.
[62]李胜涛,等.李明富教授治疗冠心病经验纂要.四川中医,2004；22(8)：2.
[63]单书健,等.古今名医临证金鉴-胸痹心痛卷.北京：中国中医出版社,1999.368.
[64]马爱群,等.心血管病学.北京：人民卫生出版社,2005.234-338,582-588.
[65]史载祥,等.现代中医心血管病学.北京：人民卫生出版社,2006.3-166.
[66]黄衍寿,等.活血化瘀药治疗冠心病研究进展.中国处方药,2006；12(45)：41-43.
[67]刘建民.颈动脉粥样硬化斑块形成原因的研究进展.实用医药杂志,2009：26(2)：67-68.
[68]Haverkate F. Are C-reactive protein and fibrinogen risk factor? In: Vander Wall E. E. (eds), Vascular medicine. Kluwer Academic Publishers, Printed in the Netherlands,1997,13-21.
[69]罗尧岳,周小青.活血化瘀药防治疗动脉粥样硬化研究进展[J].湖南中医学院学报,2002,22(3)：66.
[70]杨永宗.中国动脉粥样硬化病理生理学研究进展[J].中国动脉硬化杂志,2004,12(4)：481-489.
[71]葛华,王建明.通心络胶囊对冠心病血小板及血流变学的影响[J].中国新药杂志,1998,7(7)：12.
[72]刘小明,许亮,包凌云,等.2型糖尿病患者动脉内膜中层厚度与血液流变学的相关性研究(J)浙江中西医结合杂志.2009,19(2)：77-78
[73]杨云霞,罗晓惠,周莉.颈动脉粥样硬化与血液流变学相关性分析[J].云南医药.2009,30(3)：319-320
[74]黄文权.冠心病气滞血瘀等证型与血黏度等客观指标的相关性探讨[J].实用中西医结合杂志,1990(5)：307.
[75]刘煜德,吴辉,吴伟,等.黄连解毒汤对高胆固醇兔血液流变学和动脉粥样硬化干预作用[J].中国中医药杂志.2009,34(5)：600-604
[76]王玉萍,路浩,徐岷.动脉粥样硬化性缺血性脑卒中血液流变学及相关危险因素[J].中国实用神经疾病杂志,2007,10(3)：75.
[77]朱丽凤,张学军,包广宇.冠心病、缺血性脑血管疾病患者的血液流变学改变[J].中国血液流变学杂志,2007,17(3)：487.
[78]李王平,付正良,牛敬宪.水虫半夏汤治疗颈动脉粥样硬化(J).中国中医药现代远程教育,2008,6(10)：1192
[79]陈咸川,谢吟灵,吴晨,范代丽.益气活血化痰通络方治疗颈动脉硬化30例(J)陕西中医,2006,27(2)：187-189
[80]周仲瑛,金妙文,吴敏.滋肾养肝化痰消瘀法治疗动脉粥样硬化42例的临床研究[J].江苏中医药,2003,24(3)：13-15.
[81]赵萍,陈浩,洪永敦.温胆泄浊法对痰浊型高血压病患者血管内皮舒张功能与粥样硬化改善作用的超声研究[J].中国中西医结合杂志,2007,27(1)：21-24.
[82]王健.化痰祛瘀片对冠心病颈动脉粥样硬化影响的观察.上海中医药杂志.2003,(02)：37-38
[83]张聚府,王月芬,毋凡,薛文俊.育阴逐瘀汤治疗颈动脉粥样硬化24例(J).国医论坛,2002,17(2)：32
[84]杨焕斌,王春兰,吴素娟.冠心Ⅱ号治疗颈动脉粥样硬化斑块的临床研究(J)中国中医药科技,2005,12(1)：43-44
[85]顾耘.软脉煎治疗颈动脉粥样硬化的临床研究(J).辽宁中医杂志,2004,31(8)：634-636
[86]党毓起,吴青霞,刘军.健脾补肾消瘀祛毒法治疗颈动脉粥样硬化40例临床研究[J].实用中医内科杂志,2006,20(6)：654-655.
[87]周强,冯健兰.地黄饮子治疗颈动脉粥样硬化斑块的疗效及对血内皮素、丙二醛和C反应蛋白的影响[J].中国全科医学,2006,9(4)：335-337.
[88]张斌霞,史兵伟,张亦民.血脉通颗粒治疗颈动脉硬化症临床研究[J].辽宁中医杂志,2006,33(11)：1440-1441.
[89]陆小青.益肾活血通脉汤治疗颈动脉粥样硬化的临床观察[J].吉林中医药.2004,24(5)：12-13
[90]李帆,郭海芳.心灵丸对动脉粥样硬化患者颈动脉超声相关指标的影响(J)中国中医急症,2007,16(7)：784-785
[91]杜志刚1,姜鸿雁.加味四妙勇安汤治疗脑梗死患者颈动脉粥样硬化斑块疗效观察(J).辽宁中医杂志,2008,35(3)：393-394
[92]董国菊,刘剑刚,史大卓.精制血府胶囊对颈动脉粥样硬化患者颈动脉超声相关指标的影响[J].中国中西医结合杂志.2005,25(5)：397-399
[93]黄晓松,杨期东,龙光喻,等.通心络胶囊对颈动脉粥样硬化不稳定斑块影响的临床研究[J].疑难病杂志,2007,6(5)：267-269.
[94]莫颖敏,韩敏,谢胜芳,等.血脂康对短暂性脑缺血发作患者颈动脉粥样硬化斑块和血脂的影响[J].临床神经病学杂志,2006,19(2)：133-135.
[95]王炯波,秦学军,孙丽萍.通心络胶囊对动脉粥样硬化软斑块的临床疗效观察(J ).潍坊医学院学报.2008,30(3)：271-272.
[96]李春燕,黄淑田.颈动脉超声预测冠心病的研究进展(J).心血管病学进展,2006,27 (Suppl 1):1-3
[97]Ghiadoni L, Taddei S, Vixdis A. Endothelial function and common carotid artery wall thickening in patients with essential hypertension[J] Hypertension,1998,32 (1):25-32.
[98]曹志友,任旷,曲保忠,李中言.冠心病与颈动脉粥样硬化的相关性分析(J)中西医结合心脑血管病杂志,2003,1(7)：383-384
[99]栾霁冬,刘连沫.冠心病患者颈动脉粥样硬化检测及意义(J).黑龙江医学,2003,11(27)：518-519
[100]袁志华,桑更生,崔勇.超声检测颈动脉对冠心病的预诊断价值(J).实用全科医学,2006,4(1)：25-26
[101]张红菊,王浩，江勇，段福建，夏明钰.彩色多普勒超声对心绞痛患者颈动脉病变的初步分析(J).中国超声医学杂志,2007,23(8)：596-598
[102]徐欣,杨志健,郑义通,徐默玲,杨承健,雍永宏.超声检测颈动脉粥样硬化与冠心病心脏事件的关系(J).《临床荟萃》,2003,18(15)：844-847
[103]彭跃华,徐亮,靳建华,张瑛.超声检测颈动脉粥样硬化与冠状动脉病变的关系(J).实用诊断与治疗杂志,2005,19(9)：664-665
[104]黄江南,宋梦莹.颈动脉内中膜厚度与冠心病的相关性(J).海南医学,2009,20(4)：6-8.
[105]曲凤玉,于德成,欧芹,等.熟地黄不同溶媒提取液对D-半乳糖衰老小鼠脑SOD和MDA影响的实验研究[J].黑龙江医药科学.1998,21(5)：6-7
[106]张鹏霞,曲凤玉,欧芹,等.熟地提取液对衰老模型小鼠脑组织NOS、NO、SOD、LPD的影响[J].中国老年学杂志,1999,(3)：174.
[107]武冬梅,付正宗,楚振升等,熟地黄水提液对小鼠心肌LPF、GSH-Px的影响[J]黑龙江医药科学,2000,(1)：37.
[108]黄霞,庆慧,王惠森,等.熟地水煎剂及其提取物对小鼠外周血象影响的比较研究[J].中成药.2002,24(2)：111-113
[109]马健,樊巧玲,木村正康.生地黄对“阴虚”模型小鼠腹腔巨噬细胞Ⅰa抗原表达的影响.中药药理与临床,1998,14(2)：22～24
[110]陈丁丁,戴德哉,章涛.地黄煎剂消退L-甲状腺素诱发的大鼠心肌肥厚并抑制其升高的心、脑线粒体Ca2+,Mg2+-ATP酶活力.中药药理与临床,1997,13(4)：27-28
[111]陈丁丁,戴德哉,章涛.地黄煎剂抑制异丙肾上腺素诱发的缺血大鼠脑Ca2+, Mg2+-ATP酶活力升高.中药药理与临床,1996,12(5)：22～24
[112]常吉梅,刘秀玉,常吉辉.地黄对血压调节作用的实验研究.时珍国医国药研究,1998,9(5)：416～417
[113]Guo J N, Weng X C, Wu H, et al. Antioxidants from a Chinese medicinal herb-Psoralea corylifolia L. [J]. Food Chemistry,2005,91 (2):287-292.
[114]Pae H O, Cho H, Oh G S, et al. Bakuchiol from Psoraleacorylifolia inhibits the expression of inducible nitric oxidesynthase gene via the inactivation of nuclear transcription factor-κB in RAW 264.7 macrophages[J] International Immunopharmacology,2001,1:1849-1855.
[115]朱大元.补骨脂化学成分的研究[J].药学学报,1979,14(10)：605-611.
[116]管淑玉,苏薇薇.何首乌的化学成分和药理作用研究进展[J].中南药学.2008,6(4)：454-455
[117]崔映宇,李焰焰.何首乌研究进展[J].阜阳师范学院学报·自然科学版,2004,21(4)：24-27.
[118]赵玲,李雅莉,张丽,等.二苯乙烯苷对高胆固醇血症致β-淀粉样肽增高大鼠模型的影响[J].中国药理学通报,2005,21(1)：49-52.
[119]莫志江,潘毓宁,潘洪平.何首乌及其制剂延缓衰老的药效学研究[J].时珍国药研究,1995,6(4)：49-51.
[120]王南,朱宇,蔡海江.首乌组方对动脉平滑肌细胞增殖的抑制作用[J].南京医科大学学报(中文版),1996,16(1)：21-23.
[121]陈万生,刘文庸,杨根金,等.制首乌中1个新的四羟基二苯乙烯苷的结构鉴定及其心血管活性研究[J].药学学报,2000,35(12)：906-908.
[122]张云峰,叶小芳.牛膝多糖的生物学功能研究进展[J].畜牧兽医杂.2007,26(4)：29-30
[123]李学林,李威,陈国华,等.牛膝活血作用的实验研究[J].中医研究,1990,3(2)：27
[124]Guptoi SS, Bhagwat AW, Ram AK. Cardiac stimldant activity of the asponin of achyranthes aspera (linn) [J]. Indian J Med Res,1972,62 (3):462.
[125]陈红,石圣洪.中药川、怀牛膝对小鼠微循环及大鼠血液流变学的影响.中国微循环.1988,2(3)：182
[126]李小川,郭胜民,孙海燕,等.怀牛膝总皂甙镇痛作用研究.陕西医学杂志,1999,28(12)：735-736.
[127]沈雅琴.半夏的抗腹泻和抗炎作用[J].中药药理与临床,1998,14(2)：29
[128]刘继林.水半夏与半夏部分药理作用的对比研究[J].成都中医药学院学报,1989,12 (2)：41
[129]洪行球.半夏降血脂作用研究[J].浙江中医学院学报,1995,19(2)：28-29
[130]沈雅琴,张明发.半夏的镇痛、抗溃疡和抗血栓作用的形成[J].中国生化药物杂志,1998,19(3)：141
[131]李玉先,刘晓东,朱照静.半夏药理作用的研究述要.辽宁中医学院学报,2004,6(6)：459-460.
[132]毛淑杰,吴连英,程丽萍.天南星(虎掌南星)生、制品镇静抗惊厥作用比较研究[J].中国中药杂志,1994,19(4)：218-220.
[133]王义雄,苗小春.L-缬氨酰-L-缬氨酸酐对血液灌流犬离体窦房节和乳头状肌的作用[J].中国药理学报,1986,7(5)：435-438.
[134]Chung W. A phospholipase A2 inhibiter from Arisaema amurense Max. Var. Serratum Nakai [J]. Arch Pharmacal Res,1995,18 (4):293-294.
[135]郝炎,吴连英,王孝涛.胆南星不同炮制品的药效和毒性实验研究[J].中药材,1997,20(9)：459-461.
[136]刑蜀林,李谷霞,丁建新,等.复方三生针的药理研究[J].中药通报,1987,12(9)：47.
[137]杜毅,周超凡.石菖蒲临床应用与实验研究的概述[J].内蒙古中医药.1993,12(1)：401
[138]周晓圆,李芮.药用菖蒲研究近况[J].山东中医学院学报.1994,18(4)：270.
[139]杜毅,周超凡.石菖蒲临床应用与实验研究的概述[J].内蒙古中医药.1993,12(1)：40.
[140]胡燕月,阮琴,徐叶芬,等.川芎嗪和阿魏酸对大鼠离体心脏血流动力学的影响[J].浙江师范大学学报(自然科学版)[J].2004,4(3)：182.
[141]黄美杏,陈学远,龙学明,等.川芎嗪对慢性肺心病急性加重期患者肺功能与血管活性物质的影响[J].实用医学杂志[J],2005(19)：602.
[142]周江.川芎有效成分及其药理作用研究概况.浙江中医杂志[J].2007，42(10)：615-616.
[143]欧仕益,包惠燕,蓝志东.阿魏酸及其衍生物的药理作用研究进展.中药材,2001(8)：220-221.
[144]朱全刚,胡晋红,黄瑾.阿魏酸及其衍生物的药理作用.中药材,2001(7)：199-200.
[145]陈为.三七多糖的研究进展.吉林医药学院学报.2009,30(2)：106-110
[146]邢红艳张笋.三七通舒胶囊预防脑梗死复发的临床观察及对血液流变学的影响.中华脑血管病杂志.2009,3(1)：23-25
[147]罗陆一,冯润芬,蔡敏,杨焕斌,陈鹏毅,吴泽铭,邢洁,张大创.地黄饮子对冠心病心绞痛患者血ET、MDA、CRP影响的临床研究.中国中医药科技.2004,11(6)：323-325
[148]杨焕斌,罗陆一,吴泽铭,陈鹏毅,邢洁,张大创,徐明明.地黄饮子对冠心病心绞 痛患者NO、NOS、SOD影响的临床研究.中国中医药科技.2002,9(6)：325-327
[149]杨焕斌,林坚,罗陆一.补肾法对冠心病心绞痛患者NO、NOS、ET的影响.中国中医药信息杂志.2006,13(1)：18-20
[150]杨焕斌,林坚,王彩霞,罗陆一,等.补肾法对100例冠心病心绞痛NO、NOS、SOD、MDA影响的临床研究.中医药信息.2003,20(6)：33-36
[151]陈鹏毅,周晃如,张大创,王艳玲,罗陆一.麝香保心丸对冠心病心绞痛一氧化氮、一氧化氮合酶、超氧化物歧化酶影响的临床研究.河北中医.2005,27(8)：618-620
[152]罗陆一,杨焕斌,马骋,项晓人,王耿,李晓冬,孙小玉.通脉地仙丸对垂体后叶素引起家兔急性心肌缺血的作用.中国中医药科技.2002,(6)
[153]罗陆一,杨焕斌,邱仁斌.通脉地仙丸治疗冠心病160例疗效观察.安徽中医临床杂志.2002,14(4)：140-141
[154]罗陆一,冯润芬.通脉丸对冠心病患者SOD、MDA、CRP及血脂水平的影响.中国中医药科技.2005,12(2)：71-72
[155]罗陆一,杨焕斌,冯润芬.加减神仙不老汤治疗冠心病200例临床疗效观察.中国中医药科技.2000,7(6)：387
[156]张大创,杨焕斌,罗陆一,李根,周晃如.冠心Ⅲ号对冠心病并心肌肥厚患者心绞痛、心电图的影响.山西中医.2009,25(2)：31-33
[157]杨焕斌.冠心Ⅱ号治疗颈动脉粥样硬化斑块的临床研究.中国中医药信息杂志.2004,11(2)：107-109
[158]张大创,殷建明,栾杰男,邢洁,罗陆一.通脉地仙丸稳定颈动脉粥样硬化易损斑块的临床观察.光明中医.2009,24(3)：446-447
[159]罗陆一,冯润芬,吴泽民,邢洁,张大创.温肾化痰活血法心腧穴位外治治疗冠心病心绞痛观察.中医药学刊.2006,24(6)：984-985
[160]罗陆一,冯润芬,邱仁斌,罗玫,等.脑脉通治疗颈动脉粥样硬化斑块60例临床分析.实用中医药杂志.2005,21(3)：131-132.
[161]Crouse J R. Predictive value of carotid 2-dimensional ultrasonic [J] Am J Cardiol,2001,88 (2-A):27E.
[162]徐智章.现代腹部超声诊断学[M].北京：科学出版社,2001,第一版：636-640.
[163]Crouse J R,Byington RP, Bond MG, et al. Pravastatin, lipids and atherosclerosis in carotid arteries [J]. Am J Cardiol,1995,75 (7):455-459.
[164]白民刚,谷刚,张桂英,等.川山化瘀胶囊对颈动脉斑块的临床研究(J).中西医结合心脑血管病杂志.2007,5(11)：1052-1053.
[165]贾玉勤,郑文玲,冯乐燕,等.化痰活血法治疗颈动脉斑块临床观察(J).中国中医急症.2006,15(9)：940-941.
[166]徐桂范.通脉丸治疗颈动脉粥样硬化斑块40例临床观察(J).黑龙江医 学.2008,32(6)：434-435.
[167]史载祥,等.现代中医心血管病学.北京：人民卫生出版社,2006.842-843.
[168]史载祥,等.现代中医心血管病学.北京：人民卫生出版社,2006.845-847.
[169]孙振球,等.医学统计学.北京：人民卫生出版社,第二版,2007.619-621.
[170]孙振球,等.医学统计学.北京：人民卫生出版社,第二版,2007.832-833.
[2]黄志杰,姚昌绶,俞小平.黄帝内经神农本草经中藏经脉经难经.北京：科学技术文献出版社,1999.108.
[3]葛洪.肘后备急方.北京：人民卫生出版社,1983.112.
[4]高文铸.医经病源诊法名着集成.北京：华夏出版社,1994.386.
[5]周一谋,萧佐桃.马王堆医书考注.天津：天津科学技术出版社,1988.10,16.
[6]牛兵占,肖正权.黄帝内经素问译注.北京：中医古籍出版社,2003.464.
[7]张登本,孙理军等.全注全译黄帝内经(下册)灵枢经.北京：新世界出版社,2008.138.
[8]孟景春,王新华.黄帝内经灵枢译释.上海：上海科学技术出版社,2006.119.
[9]黄志杰,姚昌绶,俞小平.黄帝内经神农本草经中藏经脉经难经.北京：科学技术文献出版社,1999.316.
[10]高文铸.医经病源诊法名着集成.北京：华夏出版社,1994.318.
[11]黄志杰,姚昌绶,俞小平.黄帝内经神农本草经中藏经脉经难经.北京：科学技术文献出版社,1999.831.
[12]赵佶.圣济总录(上册).北京：人民卫生出版社,1982.1020,1022.
[13]张家礼.金匮要略.北京：中国中医药出版社,2004.167.
[14]喻昌.医门法律.北京：人民卫生出版社,2006.98.
[15]牛兵占,肖正权.黄帝内经素问译注.北京：中医古籍出版社,2003.441.
[16]印会河,张伯讷.中医基础理论.台北：知音出版社,1981.203.
[17]张登本,孙理军等.全注全译黄帝内经(上册)素问.北京：新世界出版社，2008.535-536.
[18]黄志杰,姚昌绶,俞小平.黄帝内经神农本草经中藏经脉经难经.北京：科学技术文献出版社,1999.8.
[19]牛兵占,肖正权.黄帝内经素问译注.北京：中医古籍出版社,2003.43.
[20]孙思邈.备急千金要方.山西：山西科学技术出版社.2010
[21]牛兵占,肖正权.黄帝内经素问译注.北京：中医古籍出版社,2003.192.
[22]张登本,孙理军等.全注全译黄帝内经(上册)素问.北京：新世界出版社,2008.31.
[23]孟景春,王新华.黄帝内经灵枢译释.上海：上海科学技术出版社,2006.91.
[24]张登本,孙理军等.全注全译黄帝内经(下册)灵枢经.北京：新世界出版社,2008.176.
[25]沈金鳌.杂病源流犀烛.北京：中国中医药出版社,1994.78.
[26]王怀隐.太平圣惠方.北京：人民卫生出版社,1982.
[27]秦景明.症因脉治.北京：人民卫生出版社,2006.71
[28]黄志杰,姚昌绶,俞小平.黄帝内经神农本草经中藏经脉经难经.北京：科学技术文献出版社,1999.99.
[29]李洪涛,等.《杂病广要·胸痹心痛》.北京：中医古籍出版社,2002.1082
[30]张家礼.金匮要略.北京：中国中医药出版社,2004.168.
[31]喻昌.医门法律.北京：人民卫生出版社,2006.99.
[32]叶天士.临证指南医案.上海：上海科学技术出版社,1959.298.
[33]林佩琴.《类证治裁·胸痹》.北京：人民卫生出版社,2005.364.
[34]张家礼.金匮要略.北京：中国中医药出版社,2004.170.
[35]朱震亨.《丹溪心法·痰饮》.北京：人民卫生出版社,2005.71.
[36]张家礼.金匮要略.北京：中国中医药出版社,2004.349.
[37]王清任.医林改错.北京：人民卫生出版社,2005.40
[38]张登本,孙理军等.全注全译黄帝内经(上册)素问.北京：新世界出版社,2008.93.
[39]孟景春,王新华.黄帝内经灵枢译释.上海：上海科学技术出版社,2006.412-413.
[40]张家礼.金匮要略.北京：中国中医药出版社,2004.168-177.
[41]孙思邈.备急千金要方.北京：人民卫生出版社,1982.239-244.
[42]危亦林.世医得效方.北京：人民卫生出版社,2006.124.
[43]王肯堂.证治准绳.北京：人民卫生出版社,1991.142.
[44]林佩琴.类证治裁.北京：人民卫生出版社,2005.367.
[45]王清任.医林改错.北京：人民卫生出版社,2005.23-24.
[46]程国彭.医学心悟.北京：人民卫生出版社,2006.155.
[47]罗陆一.从肾论治冠心病机理例析.中医药学刊,2005；23(4)：588—589.
[48]罗陆一.冠心病从肾论治.中国社区医师，2003；19(22)：33.
[49]张京春.陈可冀院士治疗冠心病心绞痛学术思想与经验.中西医结合心脑血管病杂志,2005：3(7)：634—636.
[50]张京春.陈可冀院士治疗冠心病心绞痛学术思想与经验(续完).中西医结合心脑血管病杂志,2005；3(8)：712—713.
[51]吴岳.董克礼教授诊治中老年冠心病经验.湖南中医杂志,2006；22(1)：20.
[52]吴焕林.心脾相关论与心血管疾病.北京：人民卫生出版社,2004.3-120.
[53]林晓忠,等.邓铁涛教授论治冠心病规律探要.中医药学刊,2001：19(5)：412.
[54]韩学杰.沈绍功教授从痰论治冠心病经验.中国中医急症,2004；13(1)：31.
[55]刘红旭,等.名老中医心血管疾病治疗经验集.北京：军事医学科学出版社,2009.1-15.
[56]魏铁力.颜德馨教授辨治冠心病的独特经验.实用中医内科杂 志,1996：10(1)：1-3.
[57]颜干麟.颜德馨中医心脑病诊治精粹.北京：人民卫生出版社,2009.20-23.
[58]刘红旭,等.名老中医心血管疾病治疗经验集.北京：军事医学科学出版社,2009.163-170.
[59]龙云,等.程丑夫教授治疗冠心病经验.中国中医急症,2004；13(7)：450.
[60]严季澜.孔光一教授治疗冠心病的经验.贵阳中医学院学报,2006；28(6)：17.
[61]张晓军.周宜轩教授治疗冠心病经验.安徽中医学院学报,2004；23(1)：24.
[62]李胜涛,等.李明富教授治疗冠心病经验纂要.四川中医,2004；22(8)：2.
[63]单书健,等.古今名医临证金鉴-胸痹心痛卷.北京：中国中医出版社,1999.368.
[64]马爱群,等.心血管病学.北京：人民卫生出版社,2005.234-338,582-588.
[65]史载祥,等.现代中医心血管病学.北京：人民卫生出版社,2006.3-166.
[66]黄衍寿,等.活血化瘀药治疗冠心病研究进展.中国处方药,2006；12(45)：41-43.
[67]刘建民.颈动脉粥样硬化斑块形成原因的研究进展.实用医药杂志,2009：26(2)：67-68.
[68]Haverkate F. Are C-reactive protein and fibrinogen risk factor? In: Vander Wall E. E. (eds), Vascular medicine. Kluwer Academic Publishers, Printed in the Netherlands,1997,13-21.
[69]罗尧岳,周小青.活血化瘀药防治疗动脉粥样硬化研究进展[J].湖南中医学院学报,2002,22(3)：66.
[70]杨永宗.中国动脉粥样硬化病理生理学研究进展[J].中国动脉硬化杂志,2004,12(4)：481-489.
[71]葛华,王建明.通心络胶囊对冠心病血小板及血流变学的影响[J].中国新药杂志,1998,7(7)：12.
[72]刘小明,许亮,包凌云,等.2型糖尿病患者动脉内膜中层厚度与血液流变学的相关性研究(J)浙江中西医结合杂志.2009,19(2)：77-78
[73]杨云霞,罗晓惠,周莉.颈动脉粥样硬化与血液流变学相关性分析[J].云南医药.2009,30(3)：319-320
[74]黄文权.冠心病气滞血瘀等证型与血黏度等客观指标的相关性探讨[J].实用中西医结合杂志,1990(5)：307.
[75]刘煜德,吴辉,吴伟,等.黄连解毒汤对高胆固醇兔血液流变学和动脉粥样硬化干预作用[J].中国中医药杂志.2009,34(5)：600-604
[76]王玉萍,路浩,徐岷.动脉粥样硬化性缺血性脑卒中血液流变学及相关危险因素[J].中国实用神经疾病杂志,2007,10(3)：75.
[77]朱丽凤,张学军,包广宇.冠心病、缺血性脑血管疾病患者的血液流变学改变[J].中国血液流变学杂志,2007,17(3)：487.
[78]李王平,付正良,牛敬宪.水虫半夏汤治疗颈动脉粥样硬化(J).中国中医药现代远程教育,2008,6(10)：1192
[79]陈咸川,谢吟灵,吴晨,范代丽.益气活血化痰通络方治疗颈动脉硬化30例(J)陕西中医,2006,27(2)：187-189
[80]周仲瑛,金妙文,吴敏.滋肾养肝化痰消瘀法治疗动脉粥样硬化42例的临床研究[J].江苏中医药,2003,24(3)：13-15.
[81]赵萍,陈浩,洪永敦.温胆泄浊法对痰浊型高血压病患者血管内皮舒张功能与粥样硬化改善作用的超声研究[J].中国中西医结合杂志,2007,27(1)：21-24.
[82]王健.化痰祛瘀片对冠心病颈动脉粥样硬化影响的观察.上海中医药杂志.2003,(02)：37-38
[83]张聚府,王月芬,毋凡,薛文俊.育阴逐瘀汤治疗颈动脉粥样硬化24例(J).国医论坛,2002,17(2)：32
[84]杨焕斌,王春兰,吴素娟.冠心Ⅱ号治疗颈动脉粥样硬化斑块的临床研究(J)中国中医药科技,2005,12(1)：43-44
[85]顾耘.软脉煎治疗颈动脉粥样硬化的临床研究(J).辽宁中医杂志,2004,31(8)：634-636
[86]党毓起,吴青霞,刘军.健脾补肾消瘀祛毒法治疗颈动脉粥样硬化40例临床研究[J].实用中医内科杂志,2006,20(6)：654-655.
[87]周强,冯健兰.地黄饮子治疗颈动脉粥样硬化斑块的疗效及对血内皮素、丙二醛和C反应蛋白的影响[J].中国全科医学,2006,9(4)：335-337.
[88]张斌霞,史兵伟,张亦民.血脉通颗粒治疗颈动脉硬化症临床研究[J].辽宁中医杂志,2006,33(11)：1440-1441.
[89]陆小青.益肾活血通脉汤治疗颈动脉粥样硬化的临床观察[J].吉林中医药.2004,24(5)：12-13
[90]李帆,郭海芳.心灵丸对动脉粥样硬化患者颈动脉超声相关指标的影响(J)中国中医急症,2007,16(7)：784-785
[91]杜志刚1,姜鸿雁.加味四妙勇安汤治疗脑梗死患者颈动脉粥样硬化斑块疗效观察(J).辽宁中医杂志,2008,35(3)：393-394
[92]董国菊,刘剑刚,史大卓.精制血府胶囊对颈动脉粥样硬化患者颈动脉超声相关指标的影响[J].中国中西医结合杂志.2005,25(5)：397-399
[93]黄晓松,杨期东,龙光喻,等.通心络胶囊对颈动脉粥样硬化不稳定斑块影响的临床研究[J].疑难病杂志,2007,6(5)：267-269.
[94]莫颖敏,韩敏,谢胜芳,等.血脂康对短暂性脑缺血发作患者颈动脉粥样硬化斑块和血脂的影响[J].临床神经病学杂志,2006,19(2)：133-135.
[95]王炯波,秦学军,孙丽萍.通心络胶囊对动脉粥样硬化软斑块的临床疗效观察(J ).潍坊医学院学报.2008,30(3)：271-272.
[96]李春燕,黄淑田.颈动脉超声预测冠心病的研究进展(J).心血管病学进展,2006,27 (Suppl 1):1-3
[97]Ghiadoni L, Taddei S, Vixdis A. Endothelial function and common carotid artery wall thickening in patients with essential hypertension[J] Hypertension,1998,32 (1):25-32.
[98]曹志友,任旷,曲保忠,李中言.冠心病与颈动脉粥样硬化的相关性分析(J)中西医结合心脑血管病杂志,2003,1(7)：383-384
[99]栾霁冬,刘连沫.冠心病患者颈动脉粥样硬化检测及意义(J).黑龙江医学,2003,11(27)：518-519
[100]袁志华,桑更生,崔勇.超声检测颈动脉对冠心病的预诊断价值(J).实用全科医学,2006,4(1)：25-26
[101]张红菊,王浩，江勇，段福建，夏明钰.彩色多普勒超声对心绞痛患者颈动脉病变的初步分析(J).中国超声医学杂志,2007,23(8)：596-598
[102]徐欣,杨志健,郑义通,徐默玲,杨承健,雍永宏.超声检测颈动脉粥样硬化与冠心病心脏事件的关系(J).《临床荟萃》,2003,18(15)：844-847
[103]彭跃华,徐亮,靳建华,张瑛.超声检测颈动脉粥样硬化与冠状动脉病变的关系(J).实用诊断与治疗杂志,2005,19(9)：664-665
[104]黄江南,宋梦莹.颈动脉内中膜厚度与冠心病的相关性(J).海南医学,2009,20(4)：6-8.
[105]曲凤玉,于德成,欧芹,等.熟地黄不同溶媒提取液对D-半乳糖衰老小鼠脑SOD和MDA影响的实验研究[J].黑龙江医药科学.1998,21(5)：6-7
[106]张鹏霞,曲凤玉,欧芹,等.熟地提取液对衰老模型小鼠脑组织NOS、NO、SOD、LPD的影响[J].中国老年学杂志,1999,(3)：174.
[107]武冬梅,付正宗,楚振升等,熟地黄水提液对小鼠心肌LPF、GSH-Px的影响[J]黑龙江医药科学,2000,(1)：37.
[108]黄霞,庆慧,王惠森,等.熟地水煎剂及其提取物对小鼠外周血象影响的比较研究[J].中成药.2002,24(2)：111-113
[109]马健,樊巧玲,木村正康.生地黄对“阴虚”模型小鼠腹腔巨噬细胞Ⅰa抗原表达的影响.中药药理与临床,1998,14(2)：22～24
[110]陈丁丁,戴德哉,章涛.地黄煎剂消退L-甲状腺素诱发的大鼠心肌肥厚并抑制其升高的心、脑线粒体Ca2+,Mg2+-ATP酶活力.中药药理与临床,1997,13(4)：27-28
[111]陈丁丁,戴德哉,章涛.地黄煎剂抑制异丙肾上腺素诱发的缺血大鼠脑Ca2+, Mg2+-ATP酶活力升高.中药药理与临床,1996,12(5)：22～24
[112]常吉梅,刘秀玉,常吉辉.地黄对血压调节作用的实验研究.时珍国医国药研究,1998,9(5)：416～417
[113]Guo J N, Weng X C, Wu H, et al. Antioxidants from a Chinese medicinal herb-Psoralea corylifolia L. [J]. Food Chemistry,2005,91 (2):287-292.
[114]Pae H O, Cho H, Oh G S, et al. Bakuchiol from Psoraleacorylifolia inhibits the expression of inducible nitric oxidesynthase gene via the inactivation of nuclear transcription factor-κB in RAW 264.7 macrophages[J] International Immunopharmacology,2001,1:1849-1855.
[115]朱大元.补骨脂化学成分的研究[J].药学学报,1979,14(10)：605-611.
[116]管淑玉,苏薇薇.何首乌的化学成分和药理作用研究进展[J].中南药学.2008,6(4)：454-455
[117]崔映宇,李焰焰.何首乌研究进展[J].阜阳师范学院学报·自然科学版,2004,21(4)：24-27.
[118]赵玲,李雅莉,张丽,等.二苯乙烯苷对高胆固醇血症致β-淀粉样肽增高大鼠模型的影响[J].中国药理学通报,2005,21(1)：49-52.
[119]莫志江,潘毓宁,潘洪平.何首乌及其制剂延缓衰老的药效学研究[J].时珍国药研究,1995,6(4)：49-51.
[120]王南,朱宇,蔡海江.首乌组方对动脉平滑肌细胞增殖的抑制作用[J].南京医科大学学报(中文版),1996,16(1)：21-23.
[121]陈万生,刘文庸,杨根金,等.制首乌中1个新的四羟基二苯乙烯苷的结构鉴定及其心血管活性研究[J].药学学报,2000,35(12)：906-908.
[122]张云峰,叶小芳.牛膝多糖的生物学功能研究进展[J].畜牧兽医杂.2007,26(4)：29-30
[123]李学林,李威,陈国华,等.牛膝活血作用的实验研究[J].中医研究,1990,3(2)：27
[124]Guptoi SS, Bhagwat AW, Ram AK. Cardiac stimldant activity of the asponin of achyranthes aspera (linn) [J]. Indian J Med Res,1972,62 (3):462.
[125]陈红,石圣洪.中药川、怀牛膝对小鼠微循环及大鼠血液流变学的影响.中国微循环.1988,2(3)：182
[126]李小川,郭胜民,孙海燕,等.怀牛膝总皂甙镇痛作用研究.陕西医学杂志,1999,28(12)：735-736.
[127]沈雅琴.半夏的抗腹泻和抗炎作用[J].中药药理与临床,1998,14(2)：29
[128]刘继林.水半夏与半夏部分药理作用的对比研究[J].成都中医药学院学报,1989,12 (2)：41
[129]洪行球.半夏降血脂作用研究[J].浙江中医学院学报,1995,19(2)：28-29
[130]沈雅琴,张明发.半夏的镇痛、抗溃疡和抗血栓作用的形成[J].中国生化药物杂志,1998,19(3)：141
[131]李玉先,刘晓东,朱照静.半夏药理作用的研究述要.辽宁中医学院学报,2004,6(6)：459-460.
[132]毛淑杰,吴连英,程丽萍.天南星(虎掌南星)生、制品镇静抗惊厥作用比较研究[J].中国中药杂志,1994,19(4)：218-220.
[133]王义雄,苗小春.L-缬氨酰-L-缬氨酸酐对血液灌流犬离体窦房节和乳头状肌的作用[J].中国药理学报,1986,7(5)：435-438.
[134]Chung W. A phospholipase A2 inhibiter from Arisaema amurense Max. Var. Serratum Nakai [J]. Arch Pharmacal Res,1995,18 (4):293-294.
[135]郝炎,吴连英,王孝涛.胆南星不同炮制品的药效和毒性实验研究[J].中药材,1997,20(9)：459-461.
[136]刑蜀林,李谷霞,丁建新,等.复方三生针的药理研究[J].中药通报,1987,12(9)：47.
[137]杜毅,周超凡.石菖蒲临床应用与实验研究的概述[J].内蒙古中医药.1993,12(1)：401
[138]周晓圆,李芮.药用菖蒲研究近况[J].山东中医学院学报.1994,18(4)：270.
[139]杜毅,周超凡.石菖蒲临床应用与实验研究的概述[J].内蒙古中医药.1993,12(1)：40.
[140]胡燕月,阮琴,徐叶芬,等.川芎嗪和阿魏酸对大鼠离体心脏血流动力学的影响[J].浙江师范大学学报(自然科学版)[J].2004,4(3)：182.
[141]黄美杏,陈学远,龙学明,等.川芎嗪对慢性肺心病急性加重期患者肺功能与血管活性物质的影响[J].实用医学杂志[J],2005(19)：602.
[142]周江.川芎有效成分及其药理作用研究概况.浙江中医杂志[J].2007，42(10)：615-616.
[143]欧仕益,包惠燕,蓝志东.阿魏酸及其衍生物的药理作用研究进展.中药材,2001(8)：220-221.
[144]朱全刚,胡晋红,黄瑾.阿魏酸及其衍生物的药理作用.中药材,2001(7)：199-200.
[145]陈为.三七多糖的研究进展.吉林医药学院学报.2009,30(2)：106-110
[146]邢红艳张笋.三七通舒胶囊预防脑梗死复发的临床观察及对血液流变学的影响.中华脑血管病杂志.2009,3(1)：23-25
[147]罗陆一,冯润芬,蔡敏,杨焕斌,陈鹏毅,吴泽铭,邢洁,张大创.地黄饮子对冠心病心绞痛患者血ET、MDA、CRP影响的临床研究.中国中医药科技.2004,11(6)：323-325
[148]杨焕斌,罗陆一,吴泽铭,陈鹏毅,邢洁,张大创,徐明明.地黄饮子对冠心病心绞 痛患者NO、NOS、SOD影响的临床研究.中国中医药科技.2002,9(6)：325-327
[149]杨焕斌,林坚,罗陆一.补肾法对冠心病心绞痛患者NO、NOS、ET的影响.中国中医药信息杂志.2006,13(1)：18-20
[150]杨焕斌,林坚,王彩霞,罗陆一,等.补肾法对100例冠心病心绞痛NO、NOS、SOD、MDA影响的临床研究.中医药信息.2003,20(6)：33-36
[151]陈鹏毅,周晃如,张大创,王艳玲,罗陆一.麝香保心丸对冠心病心绞痛一氧化氮、一氧化氮合酶、超氧化物歧化酶影响的临床研究.河北中医.2005,27(8)：618-620
[152]罗陆一,杨焕斌,马骋,项晓人,王耿,李晓冬,孙小玉.通脉地仙丸对垂体后叶素引起家兔急性心肌缺血的作用.中国中医药科技.2002,(6)
[153]罗陆一,杨焕斌,邱仁斌.通脉地仙丸治疗冠心病160例疗效观察.安徽中医临床杂志.2002,14(4)：140-141
[154]罗陆一,冯润芬.通脉丸对冠心病患者SOD、MDA、CRP及血脂水平的影响.中国中医药科技.2005,12(2)：71-72
[155]罗陆一,杨焕斌,冯润芬.加减神仙不老汤治疗冠心病200例临床疗效观察.中国中医药科技.2000,7(6)：387
[156]张大创,杨焕斌,罗陆一,李根,周晃如.冠心Ⅲ号对冠心病并心肌肥厚患者心绞痛、心电图的影响.山西中医.2009,25(2)：31-33
[157]杨焕斌.冠心Ⅱ号治疗颈动脉粥样硬化斑块的临床研究.中国中医药信息杂志.2004,11(2)：107-109
[158]张大创,殷建明,栾杰男,邢洁,罗陆一.通脉地仙丸稳定颈动脉粥样硬化易损斑块的临床观察.光明中医.2009,24(3)：446-447
[159]罗陆一,冯润芬,吴泽民,邢洁,张大创.温肾化痰活血法心腧穴位外治治疗冠心病心绞痛观察.中医药学刊.2006,24(6)：984-985
[160]罗陆一,冯润芬,邱仁斌,罗玫,等.脑脉通治疗颈动脉粥样硬化斑块60例临床分析.实用中医药杂志.2005,21(3)：131-132.
[161]Crouse J R. Predictive value of carotid 2-dimensional ultrasonic [J] Am J Cardiol,2001,88 (2-A):27E.
[162]徐智章.现代腹部超声诊断学[M].北京：科学出版社,2001,第一版：636-640.
[163]Crouse J R,Byington RP, Bond MG, et al. Pravastatin, lipids and atherosclerosis in carotid arteries [J]. Am J Cardiol,1995,75 (7):455-459.
[164]白民刚,谷刚,张桂英,等.川山化瘀胶囊对颈动脉斑块的临床研究(J).中西医结合心脑血管病杂志.2007,5(11)：1052-1053.
[165]贾玉勤,郑文玲,冯乐燕,等.化痰活血法治疗颈动脉斑块临床观察(J).中国中医急症.2006,15(9)：940-941.
[166]徐桂范.通脉丸治疗颈动脉粥样硬化斑块40例临床观察(J).黑龙江医 学.2008,32(6)：434-435.
[167]史载祥,等.现代中医心血管病学.北京：人民卫生出版社,2006.842-843.
[168]史载祥,等.现代中医心血管病学.北京：人民卫生出版社,2006.845-847.
[169]孙振球,等.医学统计学.北京：人民卫生出版社,第二版,2007.619-621.
[170]孙振球,等.医学统计学.北京：人民卫生出版社,第二版,2007.832-833.